MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival

Tumor Biology

Volumn 36, Issue 10, 2015, Pages 8159-8166

  Xu, Zheng ^a   Yu, Yan Qiu ^b   Ge, Yu Zheng ^a   Zhu, Jia Geng ^a   Zhu, Meng ^a   Zhao, You Cai ^a   Xu, Lu Wei ^a   Yang, Xiao Bing ^a   Geng, Li Guo ^a   Dou, Quan Liang ^a   Jia, Rui Peng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; microRNA; Muscle invasive bladder cancer; Prognosis

Indexed keywords

MICRORNA; MICRORNA 125B 1; MICRORNA 193A; MICRORNA 99A; MICRORNA LET 7C; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; BLADDER TUMOR; CANCER STAGING; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; MUSCLE TUMOR; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION;

AGED; BIOMARKERS, TUMOR; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84944274799     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3559-z     Document Type: Article

References (41)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.
2. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41. doi:10.1016/j.eururo.2012.07.033.
3. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, et al. Bladder cancer. J Natl Compr Cancer Netw: JNCCN. 2013;11(4):446–75.
4. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92. doi:10.1016/j.eururo.2013.11.046.
5. Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015. doi:10.1016/j.eururo.2015.01.032.
6. van Rhijn BW, Catto JW, Goebell PJ, Knuchel R, Shariat SF, van der Poel HG, et al. Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. Urol Oncol. 2014;32(7):1078–87. doi:10.1016/j.urolonc.2014.07.002.
7. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65. doi:10.1038/nrd4140.
8. Bolton EM, Tuzova AV, Walsh AL, Lynch T, Perry AS. Noncoding RNAs in prostate cancer: the long and the short of it. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2014;20(1):35–43. doi:10.1158/1078-0432.CCR-13-1989.
9. Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell. 2013;153(3):516–9. doi:10.1016/j.cell.2013.04.003.
10. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671–81. doi:10.1016/j.eururo.2011.01.044.
11. Guo Z, Zhao C, Wang Z. MicroRNAs as ideal biomarkers for the diagnosis of lung cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(10):10395–407. doi:10.1007/s13277-014-2330-1.
12. Chen WX, Hu Q, Qiu MT, Zhong SL, Xu JJ, Tang JH, et al. miR-221/222: promising biomarkers for breast cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(3):1361–70. doi:10.1007/s13277-013-0750-y.
13. Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M, Enokida H. Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol. 2013;10(7):396–404. doi:10.1038/nrurol.2013.113.
14. Ge YZ, Wu R, Xin H, Zhu M, Lu TZ, Liu H, et al. A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2015. doi:10.1007/s00432-015-1927-0.
15. Ge YZ, Xu LW, Xu Z, Wu R, Xin H, Zhu M, et al. Expression profiles and clinical significance of microRNAs in papillary renal cell carcinoma: a STROBE-compliant observational study. Medicine. 2015;94(16), e767. doi:10.1097/MD.0000000000000767.
16. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009;69(21):8472–81. doi:10.1158/0008-5472.CAN-09-0744.
17. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851–60. doi:10.1158/0008-5472.CAN-08-4043.
18. Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer J Int du Cancer. 2013;132(11):2479–91. doi:10.1002/ijc.27949.
19. Segersten U, Spector Y, Goren Y, Tabak S, Malmstrom PU. The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer. Urol Oncol. 2014;32(5):613–8. doi:10.1016/j.urolonc.2013.11.001.
20. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22. doi:10.1038/nature12965.
21. Zhao Y, Simon R. BRB-ArrayTools data archive for human cancer gene expression: a unique and efficient data sharing resource. Cancer Informat. 2008;6:9–15.
22. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633–41. doi:10.1016/S1470-2045(12)70102-X.
23. Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Goel MM, et al. Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(8):8243–8. doi:10.1007/s13277-014-2026-6.
24. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32(3–4):623–42. doi:10.1007/s10555-013-9441-9.
25. Chen WX, Zhong SL, Ji MH, Pan M, Hu Q, Lv MM, et al. MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(4):2883–92. doi:10.1007/s13277-013-1417-4.
26. Chistiakov DA, Chekhonin VP. Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(9):8425–38. doi:10.1007/s13277-014-2262-9.
27. Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM. The evolving understanding of microRNA in bladder cancer. Urol Oncol. 2014;32(1):41 e31–40. doi:10.1016/j.urolonc.2013.04.014.
28. Liu J, Zhu H, Yang X, Ge Y, Zhang C, Qin Q, et al. MicroRNA-21 is a novel promising target in cancer radiation therapy. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(5):3975–9. doi:10.1007/s13277-014-1623-8.
29. Chiu SC, Chung HY, Cho DY, Chan TM, Liu MC, Huang HM, et al. Therapeutic potential of microRNA let-7: tumor suppression or impeding normal stemness. Cell Transplant. 2014;23(4–5):459–69. doi:10.3727/096368914X678418.
30. Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka H, et al. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One. 2014;9(2), e84311. doi:10.1371/journal.pone.0084311.
31. Canturk KM, Ozdemir M, Can C, Oner S, Emre R, Aslan H, et al. Investigation of key miRNAs and target genes in bladder cancer using miRNA profiling and bioinformatic tools. Mol Biol Rep. 2014;41(12):8127–35. doi:10.1007/s11033-014-3713-5.
32. Feng Y, Kang Y, He Y, Liu J, Liang B, Yang P, et al. microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. BMC Urol. 2014;14:50. doi:10.1186/1471-2490-14-50.
33. Zhang L, Li X, Ke Z, Huang L, Liang Y, Wu J, et al. MiR-99a may serve as a potential oncogene in pediatric myeloid leukemia. Cancer Cell Int. 2013;13(1):110. doi:10.1186/1475-2867-13-110.
34. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer J Int du Cancer. 2009;124(9):2236–42. doi:10.1002/ijc.24183.
35. Wu JG, Wang JJ, Jiang X, Lan JP, He XJ, Wang HJ, et al. MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis. Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2014. doi:10.1007/s10120-014-0421-8.
36. Fu Q, Liu Z, Pan D, Zhang W, Xu L, Zhu Y, et al. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci. 2014;105(11):1427–34. doi:10.1111/cas.12507.
37. Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, et al. A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr-Relat Cancer. 2013;20(6):809–23. doi:10.1530/ERC-13-0357.
38. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, et al. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem. 2012;287(8):5639–49. doi:10.1074/jbc.M111.291229.
39. Lv L, Li Y, Deng H, Zhang C, Pu Y, Qian L, et al. MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett. 2015;357(1):105–13. doi:10.1016/j.canlet.2014.11.002.
40. Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, et al. miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway. Mol Cancer. 2014;13:234. doi:10.1186/1476-4598-13-234.
41. Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol. 2014;32(1):41 e1–9. doi:10.1016/j.urolonc.2013.04.011.